A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

NCT04699669 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Subcutaneous Fat

Interventions

DRUG: CBL-514, placebo
DRUG: CBL-514, placebo
DRUG: CBL-514

Sponsor

Caliway Biopharmaceuticals Co., Ltd.